ScholarIQanswers from OpenAlex & ORCID
Aikou Okamoto
ResearcherPublications, citations & collaboration network
Aikou Okamoto is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Aikou Okamoto have?
ScholarIQindexed works
Aikou Okamoto has 619 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Aikou Okamoto have?
ScholarIQcitation count
Aikou Okamoto has 19,723 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Aikou Okamoto?
ScholarIQh-index
Aikou Okamoto has an h-index of 53 in OpenAlex.
What is the i10-index of Aikou Okamoto?
ScholarIQi10-index
Aikou Okamoto has an i10-index of 179 in OpenAlex.
What is the ORCID of Aikou Okamoto?
ScholarIQorcid
The ORCID for Aikou Okamoto is on the source record.
What is the OpenAlex record for Aikou Okamoto?
ScholarIQopenalex
The OpenAlex for Aikou Okamoto is on the source record.
What are the most-cited papers on Aikou Okamoto?
ScholarIQmost cited works
The landscape of somatic copy-number alteration across human cancers
Rameen Beroukhim, Craig H. Mermel, Dale Porter, Guo Wei, Soumya Raychaudhuri, Jerry Donovan, Jordi Barretina, Jesse S. Boehm, Jennifer Dobson, Mitsuyoshi Urashima, Kevin T. Mc Henry, Reid M. Pinchback, Azra H. Ligon, Yoon‐Jae Cho, Leila Haery, Heidi Greulich, Michael Reich, Wendy Winckler, Michael S. Lawrence, Barbara A. Weir, Kumiko Tanaka, Derek Y. Chiang, Adam J. Bass, Alice Loo, Carter Hoffman, John R. Prensner, Ted Liefeld, Qing Gao, Derek Yecies, Sabina Signoretti, Elizabeth A. Maher, Frederic J. Kaye, Hidefumi Sasaki, Joel E. Tepper, Jonathan A. Fletcher, Josep Tabernero, José Baselga, Ming‐Sound Tsao, Francesca Demichelis, Mark A. Rubin, Pasi A. Jänne, Mark J. Daly, Carmelo Nucera, Ross L. Levine, Benjamin L. Ebert, Stacey Gabriel, Anil K. Rustgi, Cristina R. Antonescu, Marc Ladanyi, Anthony Letai, Levi A. Garraway, Massimo Loda, David G. Beer, Lawrence D. True, Aikou Okamoto, Scott L. Pomeroy, Samuel Singer, Todd R. Golub, Eric S. Lander, Gad Getz, William R. Sellers, Matthew Meyerson
Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer
Robert L. Coleman, Gini F. Fleming, Mark F. Brady, Elizabeth M. Swisher, Karina Dahl Steffensen, Michael Friedländer, Aikou Okamoto, Kathleen N. Moore, Noa Ben-Baruch, Theresa L. Werner, Noelle Cloven, Ana Oaknin, Paul DiSilvestro, Mark A. Morgan, Joo‐Hyun Nam, Charles A. Leath, Shibani Nicum, Andrea R. Hagemann, Ramey D. Littell, David Cella, Sally Baron‐Hay, Jesús García-Donás, Mika Mizuno, Katherine M. Bell‐McGuinn, Danielle Sullivan, Bruce Allen Bach, Sudipta Bhattacharya, Christine K. Ratajczak, Peter Ansell, Minh H. Dinh, Carol Aghajanian, Michael A. Bookman
High-Risk Ovarian Cancer Based on 126-Gene Expression Signature Is Uniquely Characterized by Downregulation of Antigen Presentation Pathway
Kosuke Yoshihara, Tatsuhiko Tsunoda, Daichi Shigemizu, Hiroyuki Fujiwara, Masayuki Hatae, Hisaya Fujiwara, Hideaki Masuzaki, Hidetaka Katabuchi, Yosuke Kawakami, Aikou Okamoto, Takayoshi Nogawa, Noriomi Matsumura, Yasuhiro Udagawa, Tsuyoshi Saito, Hiroaki Itamochi, Masashi Takano, Etsuko Miyagi, Tamotsu Sudo, Kimio Ushijima, Haruko Iwase, Hiroyuki Seki, Yasuhisa Terao, Takayuki Enomoto, Mikio Mikami, Kohei Akazawa, Hitoshi Tsuda, Takuya Moriya, Atsushi Tajima, Ituro Inoue, Kenichi Tanaka